354 related articles for article (PubMed ID: 16731831)
1. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy.
Ilnytska O; Lyzogubov VV; Stevens MJ; Drel VR; Mashtalir N; Pacher P; Yorek MA; Obrosova IG
Diabetes; 2006 Jun; 55(6):1686-94. PubMed ID: 16731831
[TBL] [Abstract][Full Text] [Related]
2. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice.
Drel VR; Pacher P; Vareniuk I; Pavlov I; Ilnytska O; Lyzogubov VV; Tibrewala J; Groves JT; Obrosova IG
Eur J Pharmacol; 2007 Aug; 569(1-2):48-58. PubMed ID: 17644085
[TBL] [Abstract][Full Text] [Related]
3. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats.
Obrosova IG; Drel VR; Oltman CL; Mashtalir N; Tibrewala J; Groves JT; Yorek MA
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1645-55. PubMed ID: 17911342
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.
Drel VR; Pacher P; Vareniuk I; Pavlov IA; Ilnytska O; Lyzogubov VV; Bell SR; Groves JT; Obrosova IG
Int J Mol Med; 2007 Dec; 20(6):783-92. PubMed ID: 17982684
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Li F; Szabó C; Pacher P; Southan GJ; Abatan OI; Charniauskaya T; Stevens MJ; Obrosova IG
Diabetologia; 2004 Apr; 47(4):710-7. PubMed ID: 15298348
[TBL] [Abstract][Full Text] [Related]
6. Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy.
Drel VR; Xu W; Zhang J; Pavlov IA; Shevalye H; Slusher B; Obrosova IG
Endocrinology; 2009 Dec; 150(12):5273-83. PubMed ID: 19854869
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Obrosova IG; Pacher P; Szabó C; Zsengeller Z; Hirooka H; Stevens MJ; Yorek MA
Diabetes; 2005 Jan; 54(1):234-42. PubMed ID: 15616034
[TBL] [Abstract][Full Text] [Related]
8. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.
Li F; Drel VR; Szabó C; Stevens MJ; Obrosova IG
Diabetes; 2005 May; 54(5):1514-22. PubMed ID: 15855340
[TBL] [Abstract][Full Text] [Related]
9. Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes.
Vareniuk I; Pavlov IA; Obrosova IG
Diabetologia; 2008 Nov; 51(11):2126-33. PubMed ID: 18802679
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function.
Lupachyk S; Shevalye H; Maksimchyk Y; Drel VR; Obrosova IG
Free Radic Biol Med; 2011 May; 50(10):1400-9. PubMed ID: 21300148
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion.
Terashima T; Kojima H; Chan L
FASEB J; 2012 Jan; 26(1):295-308. PubMed ID: 21978940
[TBL] [Abstract][Full Text] [Related]
12. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.
Obrosova IG; Drel VR; Pacher P; Ilnytska O; Wang ZQ; Stevens MJ; Yorek MA
Diabetes; 2005 Dec; 54(12):3435-41. PubMed ID: 16306359
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats.
Stevens MJ; Li F; Drel VR; Abatan OI; Kim H; Burnett D; Larkin D; Obrosova IG
J Pharmacol Exp Ther; 2007 Jan; 320(1):458-64. PubMed ID: 17021258
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Obrosova IG; Xu W; Lyzogubov VV; Ilnytska O; Mashtalir N; Vareniuk I; Pavlov IA; Zhang J; Slusher B; Drel VR
Free Radic Biol Med; 2008 Mar; 44(6):972-81. PubMed ID: 17976390
[TBL] [Abstract][Full Text] [Related]
15. Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency.
Vareniuk I; Pacher P; Pavlov IA; Drel VR; Obrosova IG
Int J Mol Med; 2009 May; 23(5):571-80. PubMed ID: 19360314
[TBL] [Abstract][Full Text] [Related]
16. Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.
Stavniichuk R; Drel VR; Shevalye H; Maksimchyk Y; Kuchmerovska TM; Nadler JL; Obrosova IG
Exp Neurol; 2011 Jul; 230(1):106-13. PubMed ID: 21515260
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}.
Drel VR; Lupachyk S; Shevalye H; Vareniuk I; Xu W; Zhang J; Delamere NA; Shahidullah M; Slusher B; Obrosova IG
Endocrinology; 2010 Jun; 151(6):2547-55. PubMed ID: 20357221
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase mediates diabetes-induced retinal neuropathy.
Mohammad G; Siddiquei MM; Abu El-Asrar AM
Mediators Inflamm; 2013; 2013():510451. PubMed ID: 24347828
[TBL] [Abstract][Full Text] [Related]
19. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy.
Obrosova IG; Li F; Abatan OI; Forsell MA; Komjáti K; Pacher P; Szabó C; Stevens MJ
Diabetes; 2004 Mar; 53(3):711-20. PubMed ID: 14988256
[TBL] [Abstract][Full Text] [Related]
20. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.
Dieckmann A; Kriebel M; Andriambeloson E; Ziegler D; Elmlinger M
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):132-8. PubMed ID: 22020669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
